Protocol Ledger

NCT03592641 · Phase II · TERMINATED

Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

Interventional Phase II clinical trial protocol NCT03592641 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-07-25 Enrollment: 5 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03592641
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)5 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03592641
Protocol FieldVerified Registry Value
NCT IdentifierNCT03592641
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment5 participants (ACTUAL)
Registered Start Date2019-07-25
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI